

Supplementary Table 1. Standard amino acid complete (SACC) medium for culturing *Clostridium sporogenes* ATCC 15579.

Ingredients	Concentration in Medium (mg/L or mL of solution)
Resazurin (0.01% w/v stock)	1 mL
KH ₂ PO ₄	2000
K ₂ HPO ₄	2000
MgCl ₂ · 6H ₂ O	200
(NH ₄) ₂ SO ₄	5000
L-glycine	75.1
L-valine	117.2
L-leucine	131.2
L-isoleucine	131.2
L-methionine	149.2
L-histidine	155.2
L-arginine	174.2
L-phenylalanine	165.2
L-tyrosine	181.2
L-tryptophan	204.23
NaHCO ₃ (10% w/v stock, pH 7)	25 mL
Cysteine HCl (pH 6, 5% w/v stock)	10 mL
Glucose Stock (500 mM) or ddH ₂ O ^a	40.0 mL
Trace Element Solution (pH 7.0) (g/L) ^b	10.0 mL
Nitrilotriacetic acid	12.8
FeSO ₄ · 7H ₂ O	0.1
MnCl ₂ · 4H ₂ O	0.1
CoCl ₂ · 2H ₂ O	0.17
CaCl ₂ · 2H ₂ O	0.1
ZnCl ₂	0.1
CuCl ₂	0.01
H ₃ BO ₃	0.01
NaMoO ₄ · 2H ₂ O	0.01
NaCl	1
NaSeO ₃	0.017
NiCl ₂ · 6H ₂ O	0.026
NaWO ₄ · 2H ₂ O	0.1
General Vitamin Solution (mg/L) ^b	10.0 mL
Biotin (B ₇)	2
Folic acid (B ₉)	2
Pyridoxamine HCl (B ₆)	10
Thiamine HCl (B ₁)	5
Riboflavin HCl (B ₂)	5
Nicotinic acid (B ₃)	5
Pantothenic acid (B ₅)	5
Cyanocobalamin (B ₁₂)	1
<p>-amino benzoic acid (PABA)</p>	5
Lipoic acid	5

^aMedium was prepared with either sterile water or glucose depending on the experiment.

^bMasses listed below indicate the amount of each compound per liter of stock solution.

Supplementary Table 2. Culturing HMP reference strains.

BEI number	Strain name	Genome Assembly ^a	Growth in RCM?
HM-36	<i>Clostridium</i> sp. 7_2_43FAA	Genome sequenced, assembled, and annotated	Yes
HM-79	<i>Ruminococcaceae</i> bacterium D16	Genome sequenced, assembled, and annotated	No
HM-81	<i>Acidaminococcus</i> sp. D21	Genome sequenced, assembled, and annotated	Yes
HM-84	<i>Clostridium</i> sp. D5	Genome sequenced, assembled, and annotated	Yes
HM-85	<i>Coprobacillus</i> sp. D6 (29_1)	Genome sequenced and assembled (<i>no annotation</i>)	Yes
HM-173	<i>Clostridium innocuum</i> 6_1_30	Genome sequenced (<i>no assembly or annotation</i>)	Yes
HM-176	<i>Coprobacillus</i> sp. 8_2_54BFAA	Genome sequenced (<i>no assembly or annotation</i>)	Yes
HM-178	<i>Eubacterium</i> sp. 3_1_31	Genome sequenced, assembled, and annotated	Yes
HM-182	<i>Lachnospiraceae</i> bacterium 6_1_37FAA	Genome sequenced, assembled, and annotated	Yes
HM-184	<i>Propionibacterium</i> sp. 5_U_42AFAA	Genome sequenced, assembled, and annotated	Yes
HM-229	<i>Bacillus smithii</i> 7_3_47FAA	Genome sequenced, assembled, and annotated	No
HM-231	<i>Bacillus</i> sp. 7_6_55CFAA_CT2	Genome sequenced, assembled, and annotated	Yes
HM-287	<i>Clostridium</i> sp. HGF2	Genome sequenced, assembled, and annotated	Yes
HM-303	<i>Clostridium orbiscindens</i> 1_3_50AFAA	Genome sequenced, assembled, and annotated	Yes
HM-304	<i>Collinsella</i> sp. 4_8_47FAA	Genome sequenced, assembled, and annotated	Yes
HM-306	[<i>Clostridium</i>] <i>clostridioforme</i> 2_1_49FAA	Genome sequenced, assembled, and annotated	Yes
HM-307	[<i>Clostridium</i>] <i>aldenense</i> WAL-18727	Genome sequenced (<i>no assembly or annotation</i>)	Yes
HM-308	<i>Hungatella hathewayi</i> WAL-18680	Genome sequenced, assembled, and annotated	Yes
HM-309	<i>Clostridium symbiosum</i> WAL-14163	Genome sequenced, assembled, and annotated	Yes
HM-310	<i>Clostridium perfringens</i> WAL-14572	Genome sequenced, assembled, and annotated	Yes
HM-315	<i>Clostridium citroniae</i> WAL-17108	Genome sequenced, assembled, and annotated	Yes
HM-317	[<i>Clostridium</i>] <i>clostridioforme</i> WAL-7855	Genome sequenced, assembled, and annotated	Yes
HM-318	[<i>Clostridium</i>] <i>bolteae</i> WAL-14578	Genome sequenced, assembled, and annotated	Yes
HM-319	[<i>Clostridium</i>] <i>symbiosum</i> WAL-14673	Genome sequenced, assembled, and annotated	Yes
HM-473	<i>Faecalibacterium</i> cf. <i>prausnitzii</i> KLE1255	Genome sequenced, assembled, and annotated	Yes
HM-634	<i>Clostridium</i> sp. L2-50	Genome sequenced, assembled, and annotated	No
HM-635	<i>Clostridium</i> sp. M62/1	Genome sequenced, assembled, and annotated	Yes
HM-793	<i>Coprococcus</i> sp. HPP0074	Genome sequenced, assembled, and annotated	Yes
HM-794	<i>Coprococcus</i> sp. HPP0048	Genome sequenced, assembled, and annotated	Yes

HM-1033	<i>Clostridium</i> sp. KLE 1755	Genome sequenced, assembled, and annotated	Yes
HM-1038	<i>Clostridium bolteae</i> CC43_001B	Genome sequenced (<i>no assembly or annotation</i>)	Yes
HM-1039	<i>Clostridium cadaveris</i> CC40_001C	Genome sequenced (<i>no assembly or annotation</i>)	Yes
HM-1040	<i>Clostridium cadaveris</i> CC44_001G	Genome sequenced (<i>no assembly or annotation</i>)	Yes
HM-1041	<i>Clostridium cadaveris</i> CC88A	Genome sequenced (<i>no assembly or annotation</i>)	Yes
HM-1043	<i>Clostridium lentocellum</i> CC70A	Genome sequenced (<i>no assembly or annotation</i>)	No
HM-1044	<i>Clostridium orbiscindens</i> CC43_001K	Genome sequenced (<i>no assembly or annotation</i>)	Yes
HM-1049	<i>Paenibacillus barengoltzii</i> CC33_002B	Genome sequenced (<i>no assembly or annotation</i>)	Yes
HM-1051	<i>Peptostreptococcus anaerobius</i> CC14N	Genome sequenced (<i>no assembly or annotation</i>)	Yes
HM-1056	<i>Ruminococcus gnavus</i> CC55_001C	Genome sequenced, assembled, and annotated	Yes
N/A	<i>Clostridium difficile</i> 630 Δ Erm	Genome sequenced, assembled, and annotated	Yes
N/A	<i>Clostridium sporogenes</i> ATCC 15579	Genome sequenced, assembled, and annotated	Yes

^a Genome finishing status for relevant HMP reference genomes at the onset of this study.

Supplementary Table 3. Metabolite levels in resting cell suspensions of *C. sporogenes* WT and mutants.

Substrate Added	Metabolite detected ^a											
	Phenyl-alanine	Phenyl-pyruvate	Phenyl-lactate	Phenyl-lacrylate	Tyrosine	4-OH-phenyl-pyruvate	4-OH-phenyl-lactate	4-OH-phenyl-acrylate	Tryptophan	Indole-pyruvate	Indole-lactate	Indole-acrylate
WT	Phenylpyruvate	N.D.	1650 ± 130	4.39 ± 0.16	4.31 ± 0.091							
	Phenyllactate	55 ± 9.9	40 ± 9.1	672 ± 90	N.D.							
	Phenylacrylate	N.D.	N.D.	N.D.	N.D.							
	Phenylpropionate	1270 ± 290	1080 ± 460	720 ± 320	810 ± 290							
	Phenylacetate	31.7 ± 7.0	93.3 ± 17	N.D.	N.D.							
	4-OH-phenylpyruvate					N.D.	909 ± 200	N.D.	N.D.			
	4-OH-phenyllactate					36.2 ± 10	12.2 ± 1.1	3010 ± 780	N.D.			
	4-OH-phenylacrylate					N.D.	N.D.	N.D.	N.D.			
	4-OH-phenylpropionate					492 ± 203	942 ± 38	220 ± 64	579 ± 2.5			
	4-OH-phenylacetate					18.7 ± 9.2	27.0 ± 11	N.D.	N.D.			
	Indolepyruvate									N.D.	N.D.	N.D.
	Indolelactate									11.6 ± 1.6	51.8 ± 4.2	466 ± 33
	Indoleacrylate									N.D.	N.D.	N.D.
	Indolepropionate									18.1 ± 3.1	19.2 ± 1.3	97.7 ± 5.2
Indoleacetate									N.D.	70.4 ± 1.5	N.D.	
porA	Phenylpyruvate	14.1 ± 2.8	1840 ± 270	5.76 ± 0.34	4.20 ± 0.070							
	Phenyllactate	79.7 ± 24	190 ± 22	303 ± 60	N.D.							
	Phenylacrylate	N.D.	N.D.	N.D.	N.D.							
	Phenylpropionate	452 ± 280	1390 ± 370	744 ± 180	880 ± 110							
	Phenylacetate	N.D.	N.D.	N.D.	N.D.							

	4-OH-phenylpyruvate		9.57 ± 3.4	2010 ± 990	19.2 ± 6.0	N.D.				
	4-OH-phenyllactate		48 ± 9.7	60.1 ± 10	2976 ± 740	N.D.				
	4-OH-phenylacrylate		N.D.	N.D.	3.96 ± 0.65	N.D.				
	4-OH-phenylpropionate		711 ± 230	157 ± 130	353 ± 99	868 ± 220				
	4-OH-phenylacetate		N.D.	3.07 ± 0.86	N.D.	N.D.				
	Indolepyruvate						N.D.	N.D.	N.D.	N.D.
	Indolelactate						29.6 ± 5.4	65.3 ± 8.3	498 ± 51	N.D.
	Indoleacrylate						N.D.	N.D.	0.447 ± 0.16	1200 ± 57
	Indolepropionate						18.7 ± 3.5	21.9 ± 1.8	88.8 ± 12	37.0 ± 1.5
	Indoleacetate						N.D.	77.4 ± 7.0	N.D.	N.D.
<i>fidC</i>	Phenylpyruvate	N.D.	2140 ± 140	4.29 ± 0.073	4.24 ± 0.079					
	Phenyllactate	136 ± 23	1330 ± 48	1180 ± 350	2.35 ± 0.99					
	Phenylacrylate	N.D.	N.D.	N.D.	210 ± 40					
	Phenylpropionate	N.D.	N.D.	N.D.	1140 ± 290					
	Phenylacetate	21.1 ± 6.7	91.3 ± 16	N.D.	N.D.					
	4-OH-phenylpyruvate					N.D.	1390 ± 490	N.D.	N.D.	
	4-OH-phenyllactate					336 ± 94	76.8 ± 16	2110 ± 550	N.D.	
	4-OH-phenylacrylate					N.D.	N.D.	N.D.	372 ± 50	
	4-OH-phenylpropionate					N.D.	N.D.	N.D.	912 ± 150	
	4-OH-phenylacetate					6.48 ± 4.0	9.11 ± 2.3	N.D.	N.D.	
	Indolepyruvate									N.D.
	Indolelactate						46.2 ± 7.3	85.4 ± 7.4	573 ± 19	N.D.

	Indoleacrylate					N.D.	N.D.	N.D.	1230 ± 40		
	Indolepropionate					N.D.	N.D.	N.D.	2.91 ± 0.24		
	Indoleacetate					N.D.	89.5 ± 2.7	N.D.	N.D.		
<i>acdA</i>	Phenylpyruvate	N.D.	1650 ± 140	4.25 ± 0.054	4.06 ± 0.006						
	Phenyllactate	100 ± 15	594 ± 120	870 ± 210	N.D.						
	Phenylacrylate	N.D.	N.D.	N.D.	N.D.						
	Phenylpropionate	48 ± 4.2	80 ± 9.1	N.D.	740 ± 150						
	Phenylacetate	17.7 ± 4.4	72.7 ± 13	N.D.	N.D.						
	4-OH-phenylpyruvate					N.D.	1590 ± 720	N.D.	N.D.		
	4-OH-phenyllactate					282 ± 46	44.5 ± 10	2460 ± 840	N.D.		
	4-OH-phenylacrylate					N.D.	N.D.	N.D.	N.D.		
	4-OH-phenylpropionate					N.D.	N.D.	N.D.	512 ± 140		
	4-OH-phenylacetate					5.43 ± 1.9	10.2 ± 2.0	N.D.	N.D.		
	Indolepyruvate							N.D.	N.D.		
	Indolelactate							34.9 ± 3.2	73.3 ± 0.67	554 ± 31	N.D.
	Indoleacrylate							N.D.	N.D.	N.D.	1230 ± 96
Indolepropionate							N.D.	N.D.	1.80 ± 0.068	10.6 ± 0.61	
Indoleacetate							N.D.	82.1 ± 5.9	N.D.	N.D.	
<i>fidH</i>	Phenylpyruvate	N.D.	1670 ± 60	4.54 ± 0.31	4.38 ± 0.039						
	Phenyllactate	7.83 ± 2.0	31.6 ± 1.1	358 ± 32	N.D.						
	Phenylacrylate	N.D.	N.D.	N.D.	193 ± 25						
	Phenylpropionate	68.4 ± 22	173 ± 9.6	331 ± 210	734 ± 120						

Phenylacetate	75.5 ± 12	1010 ± 100	14 ± 1.0	N.D.				
4-OH-phenylpyruvate					N.D.	1460 ± 410	N.D.	N.D.
4-OH-phenyllactate					N.D.	N.D.	1300 ± 120	N.D.
4-OH-phenylacrylate					N.D.	N.D.	228 ± 49	N.D.
4-OH-phenylpropionate					N.D.	N.D.	105 ± 15	460 ± 110
4-OH-phenylacetate					60.2 ± 2.6	57.5 ± 12	11.8 ± 1.8	N.D.
Indolepyruvate								N.D. N.D. N.D. N.D.
Indolelactate								N.D. 0.864 ± 0.54 408 ± 19 N.D.
Indoleacrylate								N.D. N.D. 1.56 ± 0.31 1120 ± 180
Indolepropionate						2.93 ± 0.18	3.86 ± 0.20	162 ± 14 22.0 ± 2.7
Indoleacetate							N.D. 81.3 ± 8.7	N.D. N.D.

^a Experiments were performed in triplicate and data are presented as means ± standard errors from the mean.

Supplementary Table 4. Summary of studies identifying AAA oxidative and reductive metabolites in host body fluids

Metabolite	Alternative name	Metabolomics studies ^{a,b}					Comments
		Wikoff ^c	Aronov ^c	Guo	Spaapen	Loke	
Phenylacetate		P_{Gly}	P_{Gln}	P _{free} , P _{Gln}	n.d.	P _{free} , U _{free}	Elevated in Phenylketonuria patients
Phenylpyruvate		n.d.	n.d.	n.d.	n.d.	n.d.	
Phenyllactate		n.d.	n.d.	P _{free}	U _{free}	n.d.	
Phenylacrylate	<i>t</i> -cinnamate	P_{Gly}	P_{Gly}	P _{Gly}	n.d.	U _{free}	Elevated in Tyrosinemia patients
Phenylpropionate	hydrocinnamate	P_{Gly}	n.d.	P _{free}	n.d.	n.d.	
4-hydroxyphenylacetate		n.d.	n.d.	P _{free}	n.d.	U _{free}	
4-hydroxyphenylpyruvate		n.d.	n.d.	n.d.	n.d.	n.d.	
4-hydroxyphenyllactate		n.d.	n.d.	P _{free}	U _{free}	n.d.	
4-hydroxyphenylacrylate	<i>p</i> -coumarate	n.d.	n.d.	n.d.	n.d.	P _{free}	
4-hydroxyphenylpropionate		n.d.	n.d.	P _{free}	n.d.	P _{free} , U _{free}	
Indoleacetate		n.d.	P_{free}	P _{free} , P _{Gln}	n.d.	n.d.	
Indolepyruvate		n.d.	n.d.	n.d.	n.d.	n.d.	
Indolelactate		n.d.	P _{free}	P _{free}	n.d.	n.d.	
Indoleacrylate		n.d.	n.d.	P _{free}	n.d.	n.d.	
Indolepropionate		P_{free}	P_{free}	P _{free}	n.d.	n.d.	

^a Letters indicate whether compounds were detected in plasma (P) or urine (U), and subscripts indicate whether they were detected as free acids (free), glycine conjugates (Gly), or glutamine conjugates (Gln).

^b References are as follows: Wikoff²⁷, Aronov²⁸, Guo²⁹, Spaapen³⁰, Loke³¹.

^c Compounds indicated in bold font were elevated in conventional vs. germ free mice (Wikoff), or in humans with intact colons vs. colectomy patients (Aronov).

Supplementary Table 5. Intron retargeting and sequencing primers for Clostron disruptions in *Clostridium sporogenes* ATCC 15579.

Gene (Locus ID)	Targeted Region ^a	Sequencing Primers ^b
<i>fldC</i> (CLOSPO_00311)	561a	311F: TGGGGAATATGATATGTTGTCTGGCATGATG 311R: TGTTCAAGCTAATCTATCCATTGGTGTATTCGC
<i>acdA</i> (CLOSPO_00312)	775s	312F: TCGCAAAAACAGATATGAGCA 312R: ACCACCATGAATTTGTAGTGC
<i>fldH</i> (CLOSPO_00316)	736s	316F: TAGGAGTTATAGGAACTGGAA 316R: TTGGTTTTTACAAGTTCCTTT
<i>porA</i> (CLOSPO_00147)	1001a	147F: TGGCTAAAGAAGAAGGTATGA 147R: TCAAACATATCACAGGCAAAA
<i>fldZ</i> (CLOSPO_02780)	1546s	2780F: TTGGCGGAAATATTGTACCAG 2780R: TTTAGCTACTTCATATGCACT

^a Targeting regions were designed using the Intron design tool on the Clostron website (<http://www.clostron.com/clostron2.php>). The regions listed indicate the nucleotide position within the gene where the intron is inserted and the a/s designation indicates whether the intron integrates in the antisense or sense strand.

^b Primers were designed to amplify the region containing the expected intron after integration. Primers were synthesized by Integrated DNA Technologies (Coralville, IA).

Supplementary Table 6. Ion transitions and instrument parameters for AAA metabolite detection.

Compound	Precursor (<i>m/z</i>)	Product (<i>m/z</i>)	Fragmentor (V)	Collision Energy (eV)
Phenylalanine				
Phenylpyruvate	163	91.1	65	5
Phenyllactate	165.1	147.1	90	9
Phenylacrylate	147	103	70	9
Phenylpropionate	149.1	105.1	80	9
Phenylacetate	135	91.1	45	5
Tyrosine				
4-OH-Phenylpyruvate	179	107	69	5
4-OH-Phenyllactate	181.1	162.9	90	9
4-OH-Phenylacrylate	163	119	76	12
4-OH-Phenylpropionate	165.1	59.1	96	9
4-OH-Phenylacetate	151	107	45	5
Tryptophan				
Indolepyruvate	202.1	174	66	1
Indolelactate	204.1	158	90	13
Indoleacrylate	186.1	142	74	13
Indolepropionate	188.1	59.1	90	13
Indoleacetate	174.1	130	74	5

Supplementary Table 7. Summary of genome assemblies

	<i>C. bolteae</i> CC43_001B	<i>C. cadaveris</i> CC40 001C	<i>C. cadaveris</i> CC44_001G	<i>C. cadaveris</i> CC88A	<i>P. anaerobius</i> CC14N
BioProject Accession Number	PRJNA71569	PRJNA71541	PRJNA71543	PRJNA71545	PRJNA71563
Combined length	6,094,255 bp	3,754,827 bp	3,562,150 bp	3,556,482 bp	2,043,901 bp
Percent GC content	49.18%	31.03%	30.97%	31.51%	30.51%
Number of sequences	102	221	142	78	18
Mean sequence length	59,748 bp	16,990 bp	25,086 bp	45,596 bp	113,550 bp
Sequence n50	1,681,030 bp	159,835 bp	307,414 bp	367,796 bp	1,583,849 bp
Sequence n90	298,438 bp	33,731 bp	58,107 bp	55,850 bp	275,990 bp
Longest sequence	2,058,090 bp	371,381 bp	485,405 bp	631,552 bp	1,583,849 bp
Average coverage depth	256X	461X	556X	569X	366X
% Corrected Reads aligned	95.5%	95.0%	95.4%	95.9%	94.2%
Phenylacetate gene cluster average coverage depth	NA	425X	629X	607X	461X
<i>rpoB</i> average coverage depth	290X	445X	684X	642X	496X
Phenylacetate dehydratase cluster GenBank accession number	N/A	BK010268	BK010335	BK010336	BK010337
RpoB GenBank accession number	BK010331	BK010269	BK010332	BK010333	BK010334

Supplementary Table 8. Oligonucleotide primers for qPCR analysis of bacterial community membership.

Organism	Genome Region ^a	qPCR Primers
<i>Bacteroides vulgatus</i> ATCC 8482	1252631 - 1252765	Bvu_qPCR_F: TCCGGCTCTGCTCGTCAAGA Bvu_qPCR_R: GCTTCCACTGCCTGCAACCA
<i>Bacteroides thetaiotaomicron</i> VPI-5482	16052 - 16154	Bth_qPCR_F: CGGGATTGTTGCGGCAGACA Bth_qPCR_R: CGCGTTCATCCGTGCCTTCA
<i>Parabacteroides distasonis</i> ATCC 8503	375224 - 375316	Pdi_qPCR_F: CGGTTTTCGTGCGGGTGATGA Pdi_qPCR_R: CGGAAGGTGGCGTTCGTGTT
<i>Edwardsiella tarda</i> ATCC 23685	526079 - 526227	Eta_qPCR_F: ACGCCCACTCACGGATCTGA Eta_qPCR_R: ACTCCCGCTCGCTCAGGTTA
<i>Eubacterium rectale</i> ATCC 33656	1863134 - 1863277	Ere_qPCR_F: GGTGCAGGCGAGTTTCCCTT Ere_qPCR_R: GCCAAACAGCCCCGACATCA
<i>Bifidobacterium breve</i> UCC2003	1357556 - 1357701	Bbr_qPCR_F: ACCCCACGCACACCAATCAC Bbr_qPCR_R: GACCGCGCCGATGAAGTTGA
<i>Clostridium scindens</i> ATCC 35704	863 - 978	Csc_qPCR_F: TTCAGGAGAAATGCCAGCCAGT Csc_qPCR_R: GTTCTGCCACGGTCGTTAGC
<i>Clostridium sporogenes</i> ATCC 15579	197533 - 197672	Csp_qPCR_F: TTGGCTCTGCACCGGGAATC Csp_qPCR_R: CTGCAAACGCCGTCCTCTT

^aqPCR primers were designed using Geneious v10.1.3 with the integrated Primer3 tool. The regions were designed to represent single copy genes and to avoid dynamic regions of the genome (e.g., not within a mobile genetic element). The primers were then used to BLAST against the other organisms in the community to ensure that no cross-priming would occur.

Supplemental References

- 27 Wikoff, W. R. *et al.* Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. *Proceedings of the National Academy of Sciences of the United States of America* **106**, 3698-3703, doi:10.1073/pnas.0812874106 (2009).
- 28 Aronov, P. A. *et al.* Colonic contribution to uremic solutes. *Journal of the American Society of Nephrology : JASN* **22**, 1769-1776, doi:10.1681/ASN.2010121220 (2011).
- 29 Guo, L. *et al.* Plasma metabolomic profiles enhance precision medicine for volunteers of normal health. *Proceedings of the National Academy of Sciences of the United States of America* **112**, E4901-4910, doi:10.1073/pnas.1508425112 (2015).
- 30 Spaapen, L. J., Ketting, D., Wadman, S. K., Bruinvis, L. & Duran, M. Urinary D-4-hydroxyphenyllactate, D-phenyllactate and D-2-hydroxyisocaproate, abnormalities of bacterial origin. *Journal of inherited metabolic disease* **10**, 383-390, doi:10.1007/BF01799981 (1987).
- 31 Loke, W. M. *et al.* A metabolite profiling approach to identify biomarkers of flavonoid intake in humans. *The Journal of nutrition* **139**, 2309-2314, doi:10.3945/jn.109.113613 (2009).